Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2

Yi, GZ; Huang, GL; Guo, ML; Zhang, XA; Wang, H; Deng, SZ; Li, YM; Xiang, W; Chen, ZY; Pan, J; Li, ZY; Yu, L; Lei, BX; Liu, YW; Qi, ST

Liu, YW (reprint author), Nanfang Hosp, Lab Precis Neurosurg, New Lab Bldg,Guangzhou Dadao Bei St, Guangzhou, Guangdong, Peoples R China.; Qi, ST (reprint author), Nanfang Hosp, Dept Neurosurg, Guangzhou Dadao Bei St, Guangzhou, Guangdong, Peoples R China

BRAIN, 2019; 142 (): 2352


The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment. Chemoresistance in glioblastoma is largely attributed to repair of temozolomide-induced DNA lesions by O-6-methylguanine-DNA methyltransferase (MGMT). However, some MGMT-deficient glioblastomas are still resistant to temozolomide, and the underlying molecular mechanisms remain unclear. We found that DYNC2H1 (DHC2) was expressed more in MGMT-deficient recurrent glioblastoma specimens and its expression strongly correlated to poor progression-free survival in MGMT promotor methylated glioblastoma patients. Furthermore, silencing DHC2, both in vitro and in vivo, enhanced temozolomide-induced DNA damage and significantly improved the efficiency of temozolomide treatment in MGMT-deficient glioblastoma. Using a combination of subcellular proteomics and in vitro analyses, we showed that DHC2 was involved in nuclear localization of the DNA repair proteins, namely XPC and CBX5, and knockdown of either XPC or CBX5 resulted in increased temozolomide-induced DNA damage. In summary, we identified the nuclear transportation of DNA repair proteins by DHC2 as a critical regulator of acquired temozolomide resistance in MGMT-deficient glioblastoma. Our study offers novel insights for improving therapeutic management of MGMT-deficient glioblastoma.

Download PDF

Full Text Link